A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk and Vivani are partnering to develop a long-acting semaglutide implant designed to improve weight loss adherence for up to a year.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Novo Nordisk entered into a partnership with Vivani to evaluate the development of a long-acting semaglutide implant designed to assist with long-term weight loss adherence. Following these initial reports, the story quieted without a definitive conclusion in the coverage.
Epilogue added 127d ago, after coverage quieted.
The brief
A new partnership has been established between the pharmaceutical company Novo Nordisk and the biotech firm Vivani to develop a tiny GLP-1 implant. According to coverage from Yahoo Finance and Pluang, this collaboration focuses on creating a long-lasting semaglutide implant intended to help users maintain weight loss. The primary goal of this medical technology is to improve long-term adherence for patients utilizing GLP-1 medications, moving away from traditional delivery methods toward a more permanent or semi-permanent solution. Several major media outlets are tracking the development of this technology.
CNBC reports that this tiny implant represents the latest strategic bet to assist patients in maintaining their weight loss. Health and Me specifies that the maker of Ozempic and Wegovy is evaluating this long-acting GLP-1 implant, noting that the device could potentially last for up to a year. The scale of the project is further emphasized by a biotech CEO who, as reported by medwatch.com, described the new Novo Nordisk partnership by stating, "This could be big." To understand the significance of this development, it is necessary to look at the current market for semaglutide, which is the active ingredient in the popular drugs Ozempic and Wegovy. These GLP-1 medications are widely used for weight management and diabetes, but maintaining long-term adherence to dosing schedules can be a challenge for many patients.
By transitioning to an implantable format, Novo Nordisk and Vivani aim to solve the issue of consistency in medication delivery, potentially removing the need for frequent injections or daily pills over a twelve-month period. Looking forward, the industry is watching how the evaluation process for this long-acting implant proceeds. Based on the reported pact between the two companies, the next steps involve the technical development and assessment of the implant's efficacy in maintaining weight loss over the stated one-year duration. While the partnership is officially signed and the objective is clear, coverage does not yet specify the exact timeline for clinical trials or the projected date for public availability of the Vivani-developed semaglutide device.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 114d ago.
Quick answers
Which companies are partnering on the GLP-1 implant?
Novo Nordisk and Vivani have signed a pact to develop the technology.
How long could the semaglutide implant potentially last?
According to Health and Me, the implant could last up to a year.
What is the primary goal of the implant?
The implant is designed to improve long-term weight loss adherence for GLP-1 users.
Coverage (5)
- Vivani develops semaglutide implant to improve long-term weight loss adherence for GLP-1 users Pluang · 129d ago
- Ozempic & Wegovy Maker To Evaluate Long-Acting GLP-1 Implant That Could Last Up To A Year Health and Me · 129d ago
- Biotech CEO on new Novo Nordisk partnership: “This could be big” medwatch.com · 129d ago
- Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant Yahoo Finance · 129d ago
- A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss CNBC · 129d ago
Topics
Related trends
Should you take GLP-1s during pregnancy? What some doctors say.
New research on GLP-1 drugs during pregnancy sparks urgent debate among doctors and patients.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
WHO Releases First Guidelines On Type 1 Diabetes In Adults: What To Know
WHO publishes its first-ever clinical guidelines for type 1 diabetes in adults, urging cheaper insulin access and multiple daily injections.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.